If they told you what they plan on doing with the
Post# of 157792
I think the partnership part is rly what’s holding us up from updates on both cancer and where NASH will go.
Also, ohm said there is more than enough share for new trials ?! How, we burned through 200 million and that was with stopping trials and cutting everyone’s pay. Who knows what the SP will be when we start selling shares. So how could we fund say a massive phase 3 NASH trial? We can’t that’s how I see it.
Finish the BLA or partner. These shares just seem like they are here to keep us afloat still. Which is insane bc it’s 350 million shares ! That’s a ton but not really when we are trading under a dollar. We barely raised any money from the 200 million we sold let’s be real here.
I still think management isn’t telling us everything and that’s what’s most frustrating.
I hope we find out more Monday.


CytoDyn Inc (CYDY) Stock Research Links
Founder & CEO | FireGate Biotech™
AI Platform: Lux Veritas™
Federal Whistleblower Case References
• HHS & SEC Whistleblower ID – HL-1412396
• DOJ Investigation Report / Whistleblower ID – 20250705-0001
• NIH Case Reference – CS1137565 ( IC IG / 50 U.S.C. § 3033 )
Website: FireGateBiotech.com
(For official updates and correspondence — I will no longer be posting here or responding via DMs)
Contact FireGate Biotech
Principal Investigator:
FG001|FG002|FG003
https://firegatebiotech.com/2025
FG-001: Integrated Triplet Immunotherapy for Functional HIV Cure
FG-002: Triplet Immunologic Modulation in Oncology — NF-κB / IL-1Ra Axis
FG-003: Neuro-Immune Repair Triplet — Concept and Combination Framework
CCR5 Antagonists & Triplet Immunotherapy Synergy in HIV
HIV Cure Pathways — Functional-Cure Framework Overview
FG-003 Neuro-Immune Repair Triplet — IP & Combination Strategy
— Jeremiah 51:36